Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | MPC2 | O95563 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7631727 | 0.87 | MAPT (0.57) | PPARGMAPTALDH1A1NPSR1MAOA | |
| SCHEMBL9564659 | 0.86 | FFAR1 (0.62) | PPARGFFAR1PPARAMPC2CYP2C8 | |
| SCHEMBL9435871 | 0.85 | PPARG (0.46) | PPARGMAPTALDH1A1NPSR1MAOA | |
| SCHEMBL13846731 | 0.83 | CA2 (0.64) | PPARGMAPTALDH1A1NPSR1MAOA | |
| SCHEMBL377496 | 0.82 | FFAR1 (0.43) | PPARGMAPTALDH1A1NPSR1MAOA | |
| SCHEMBL14281402 | 0.82 | FFAR1 (0.43) | PPARGMAPTALDH1A1NPSR1MAOA | |
| SCHEMBL9570559 | 0.82 | MAPT (0.83) | PPARGMAPTALDH1A1NPSR1MAOA | |
| SCHEMBL166570 | 0.80 | PPARG (0.74) | PPARGMAPTALDH1A1NPSR1MAOA | |
| SCHEMBL8315737 | 0.80 | MAPT (0.57) | PPARGMAPTALDH1A1NPSR1MAOA | |
| SCHEMBL290976 | 0.80 | UTRN (0.48) | PPARGMAPTALDH1A1NPSR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | PPARG 1757/4885MAPT 1785/4885ALDH1A1 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.